[go: up one dir, main page]

GB202307233D0 - Non-invasive disease detection and monitoring - Google Patents

Non-invasive disease detection and monitoring

Info

Publication number
GB202307233D0
GB202307233D0 GBGB2307233.3A GB202307233A GB202307233D0 GB 202307233 D0 GB202307233 D0 GB 202307233D0 GB 202307233 A GB202307233 A GB 202307233A GB 202307233 D0 GB202307233 D0 GB 202307233D0
Authority
GB
United Kingdom
Prior art keywords
monitoring
disease detection
invasive disease
invasive
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2307233.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOTHIAN HEALTH BOARD
University of Edinburgh
Original Assignee
LOTHIAN HEALTH BOARD
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOTHIAN HEALTH BOARD, University of Edinburgh filed Critical LOTHIAN HEALTH BOARD
Priority to GBGB2307233.3A priority Critical patent/GB202307233D0/en
Publication of GB202307233D0 publication Critical patent/GB202307233D0/en
Priority to PCT/EP2024/063285 priority patent/WO2024235997A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB2307233.3A 2023-05-15 2023-05-15 Non-invasive disease detection and monitoring Ceased GB202307233D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2307233.3A GB202307233D0 (en) 2023-05-15 2023-05-15 Non-invasive disease detection and monitoring
PCT/EP2024/063285 WO2024235997A1 (en) 2023-05-15 2024-05-14 Non-invasive disease detection and monitoring

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2307233.3A GB202307233D0 (en) 2023-05-15 2023-05-15 Non-invasive disease detection and monitoring

Publications (1)

Publication Number Publication Date
GB202307233D0 true GB202307233D0 (en) 2023-06-28

Family

ID=86872649

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2307233.3A Ceased GB202307233D0 (en) 2023-05-15 2023-05-15 Non-invasive disease detection and monitoring

Country Status (2)

Country Link
GB (1) GB202307233D0 (en)
WO (1) WO2024235997A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3752641A1 (en) * 2018-02-18 2020-12-23 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cell free dna deconvolution and use thereof
WO2023004204A2 (en) * 2021-07-23 2023-01-26 Georgetown University Use of circulating cell-free methylated dna to detect tissue damage

Non-Patent Citations (39)

* Cited by examiner, † Cited by third party
Title
BAREFOOT MELOYFER NKILITI AJSCHMIDT MOSHABI-PORAT SJAIN S ET AL.: "Cell-free, methylated DNA in blood samples reveals tissue-specific, cellular damage from radiation treatment", BIORXIV, 2022, Retrieved from the Internet <URL:https://doi.org/10.1101/2022.04.12.487966>
BLOMAIN ESMODING EJ: "Liquid Biopsies for Molecular Biology-Based Radiotherapy", INT J MOL SCI
CESCON DWBRATMAN SVCHAN SMSIU LL: "Circulating tumor DNA and liquid biopsy in oncology", NAT CANCER, vol. 1, no. 3, 2020, pages 276 - 90
CHERA BSKUMAR SBEATY BTMARRON DJEFFERYS SGREEN R ET AL.: "Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer", CLIN CANCER RES., vol. 25, no. 15, 2019, pages 4682 - 90, XP093018718, DOI: 10.1158/1078-0432.CCR-19-0211
CHOY LYLPENG WJIANG PCHENG SHYU SCYSHANG H ET AL.: "Single-molecule Sequencing Enables Long Cell-free DNA Detection and Direct Methylation Analysis for Cancer Patients", CLIN CHEM.
CHRISTENSEN EBIRKENKAMP-DEMTRODER KSETHI HSHCHEGROVA SSALARI RNORDENTOFT I ET AL.: "Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma", J CLIN ONCOL, vol. 37, no. 18, 2019, pages 1547 - 57
CITRIN DE: "Recent Developments in Radiotherapy", N ENGL J MED, vol. 377, no. 22, 2017, pages 2200 - 1
COHEN JDLI LWANG YTHOBURN CAFSARI BDANILOVA L ET AL.: "Detection and localization of surgically resectable cancers with a multi-analyte blood test", SCIENCE, vol. 359, no. 6378, 2018, pages 926 - 30, XP055687252, DOI: 10.1126/science.aar3247
DASARI AMORRIS VKALLEGRA CJATREYA CBENSON AB, 3RDBOLAND P ET AL.: "ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper", NAT REV CLIN ONCOL, vol. 17, no. 12, 2020, pages 757 - 70, XP037298632, DOI: 10.1038/s41571-020-0392-0
DE MICHINO SAPARNATHI MROSTAMI ALOK BHBRATMAN SV: "The Utility of Liquid Biopsies in Radiation Oncology", INT J RADIAT ONCOL BIOL PHYS, vol. 107, no. 5, 2020, pages 873 - 86, XP086220605, DOI: 10.1016/j.ijrobp.2020.05.008
DE PROCE ET AL.: "Development of methylation-based biomarkers for breast cancer detection by model training and validation and synthetic cell-free DNA", BIORXIV DOI 10.1101/2022.02.11.480085, 2002
DE PROCE ET AL.: "Development of methylation-based biomarkers for breast cancer detection by model training and validation and synthetic cell-free DNA", BIORXIVDOI 10.1101/2022.02.11.480085, no. 37, 2002
DE RUYSSCHER DNIEDERMANN GBURNET NGSIVA SLEE AWMHEGI-JOHNSON F: "Radiotherapy toxicity", NAT REV DIS PRIMERS, vol. 5, no. 1, 2019, pages 13
GARCIA-MURILLAS ISCHIAVON GWEIGELT BNG CHREBIEN SCUTTS RJ ET AL.: "Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer", SCI TRANSL MED, vol. 7, no. 302, 2015, pages 302ra133, XP055440860, DOI: 10.1126/scitranslmed.aab0021
HEITZER EHAQUE ISROBERTS CESSPEICHER MR: "Current and future perspectives of liquid biopsies in genomics-driven oncology", NAT REV GENET, vol. 20, no. 2, 2019, pages 71 - 88, XP036675874, DOI: 10.1038/s41576-018-0071-5
IGNATIADIS MSLEDGE GWJEFFREY SS: "Liquid biopsy enters the clinic - implementation issues and future challenges", NAT REV CLIN ONCOL, vol. 18, no. 5, 2021, pages 297 - 312, XP037434013, DOI: 10.1038/s41571-020-00457-x
KATSMAN EORLANSKI SMARTIGNANO FFOX-FISHER ISHEMER RDOR Y ET AL.: "Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing", GENOME BIOL, vol. 23, no. 1, 2022, pages 158
KEENER A: "Precision Oncology: Rethink, Aim and Fire", NATURE, vol. 585, 2020, pages S10 - S2
KERNS SLFACHAL LDORLING LBARNETT GCBARAN APETERSON DR ET AL.: "Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy", J NATL CANCER INST, vol. 112, no. 2, 2020, pages 179 - 90
KURTZ DMSCHERER FJIN MCSOO JCRAIG AFMESFAHANI MS ET AL.: "Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma", J CLIN ONCOL
LAU BTALMEDA ASCHAUER MMCNAMARA MBAI XMENG Q ET AL.: "Single molecule methylation profiles of cell-free DNA in cancer with nanopore sequencing", BIORXIV, 2022
LEHMANN-WERMAN RNEIMAN DZEMMOUR HMOSS JMAGENHEIM JVAKNIN-DEMBINSKY A ET AL.: "Identification of tissue-specific cell death using methylation patterns of circulating DNA", PROC NATL ACAD SCI USA., vol. 113, no. 13, 2016, pages E1826 - 34, XP055436315, DOI: 10.1073/pnas.1519286113
LEUNG SFCHAN KCMA BBHUI EPMO FCHOW KC ET AL.: "Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma", ANN ONCOL, vol. 25, no. 6, 2014, pages 1204 - 8
LO YMLEUNG SFCHAN LYCHAN ATLO KWJOHNSON PJ ET AL.: "Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma", CANCER RES., vol. 60, no. 9, 2000, pages 2351 - 5
LOYFER NMAGENHEIM JPERETZ ACANN GBREDNO JKLOCHENDLER A ET AL.: "A human DNA methylation atlas reveals principles of cell type-specific methylation and identifies thousands of cell type-specific regulatory elements", BIORXIV, 2022, Retrieved from the Internet <URL:https://doi.org/10.1101/2022.01.24.477547>
LV JCHEN YZHOU GQI ZTAN KRLWANG H ET AL.: "Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma", NAT COMMUN, vol. 10, no. 1, 2019, pages 3941
MOSS JMAGENHEIM JNEIMAN DZEMMOUR HLOYFER NKORACH A ET AL.: "Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease", NAT COMMUN, vol. 9, no. 1, 2018, pages 5068, XP055615527, DOI: 10.1038/s41467-018-07466-6
MUHANNA NEU DCHAN HHLDOUGLAS CTOWNSON JLDI GRAPPA MA ET AL.: "Cell-free DNA and circulating tumor cell kinetics in a pre-clinical head and neck Cancer model undergoing radiation therapy", BMC CANCER, vol. 21, no. 1, 2021, pages 1075
NEWMAN AMBRATMAN SVTO JWYNNE JFECLOV NCMODLIN LA ET AL.: "An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage", NAT MED, vol. 20, no. 5, 2014, pages 548 - 54, XP055580741, DOI: 10.1038/nm.3519
NEWMAN AMLOVEJOY AFKLASS DMKURTZ DMCHABON JJSCHERER F ET AL.: "Integrated digital error suppression for improved detection of circulating tumor DNA", NAT BIOTECHNOL., vol. 34, no. 5, 2016, pages 547 - 55, XP055802486, DOI: 10.1038/nbt.3520
PHALLEN JSAUSEN MADLEFF VLEAL AHRUBAN CWHITE J ET AL.: "Direct detection of early-stage cancers using circulating tumor DNA", SCI TRANSL MED, vol. 9, no. 403, 2017, XP055618567, DOI: 10.1126/scitranslmed.aan2415
ROSTAMI ALAMBIE MYU CWSTAMBOLIC VWALDRON JNBRATMAN SV: "Senescence, Necrosis, and Apoptosis Govern Circulating Cell-free DNA Release Kinetics", CELL REP, vol. 31, no. 13, 2020, pages 107830
SAMBROOK, J.RUSSEL, D.W.: "Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SANZ-GARCIA EZHAO EBRATMAN SVSIU LL: "Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges", SCI ADV, vol. 8, no. 4, 2022, pages eabi8618
SCHACK LMHNADERI EFACHAL LDORLING LLUCCARINI CDUNNING AM ET AL.: "A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis", BR J CANCER, vol. 126, no. 7, 2022, pages 1082 - 90, XP037792817, DOI: 10.1038/s41416-021-01670-w
SCOTT JGBERGLUND ASCHELL MJMIHAYLOV IFULP WJYUE B ET AL.: "A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study", LANCET ONCOL, vol. 18, no. 2, 2017, pages 202 - 11, XP029905054, DOI: 10.1016/S1470-2045(16)30648-9
TIE JCOHEN JDLAHOUEL KLO SNWANG YKOSMIDER S ET AL.: "Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer", N ENGL J MED, vol. 386, no. 24, 2022, pages 2261 - 72
TIE JWANG YTOMASETTI CLI LSPRINGER SKINDE I ET AL.: "Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer", SCI TRANSL MED, vol. 8, no. 346, 2016, pages 346ra92, XP055464325, DOI: 10.1126/scitranslmed.aaf6219
WARLOW SJADAMOWICZ MTHOMSON JPWESCOTT RAROBERT CCAREY LM ET AL.: "Longitudinal measurement of HPV copy number in cell-free DNA is associated with patient outcomes in HPV-positive oropharyngeal cancer", EUR J SURG ONCOL, vol. 48, no. 6, 2022, pages 1224 - 34

Also Published As

Publication number Publication date
WO2024235997A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
EP3612082A4 (en) NON-INVASIVE BLOOD PRESSURE MEASUREMENT AND MONITORING
ZA202105207B (en) Flexible sensor detection system for medical care and health
GB2597546B (en) Passenger health screening and monitoring
WO2011141765A8 (en) Diagnostic classifications of pulse signal waveform data
EP3716846A4 (en) Continuous detection and monitoring of heart arrhythmia using both wearable sensors and cloud-resident analyses
SG11202007493QA (en) Non-invasive continuous blood pressure monitoring
WO2007098070A3 (en) Non-invasive methods for evaluating retinal affecting neurodegenerative diseases
WO2010082944A3 (en) Systems and methods for imaging changes in tissue
EP2034882A4 (en) AUTOMATIC AND AMBULATING PATIENT MONITORING IN CONGESTIVE HEART FAILURE
GB201011816D0 (en) Feature characterization for breathing monitor
SG11202012518WA (en) Methods and systems for monitoring organ health and disease
IL289167A (en) 2h-indazole derivatives and their use in the treatment of disease
SA521430134B1 (en) Biomarker Monitoring Sensor and Methods of Use
IL279377A (en) Methods for assessment and early detection of stress, selecting and monitoring treatment, and new use for drugs
Peacock et al. Society of Chest Pain Centers Recommendations for the evaluation and management of the observation stay acute heart failure patient: a report from the Society of Chest Pain Centers Acute Heart Failure Committee
EP3765853C0 (en) Methods for monitoring treatment response and disease progression in subjects using circulating cells
SI3791777T1 (en) Tubular compression garment for monitoring the therapy and physiological activity of a person
GB202307233D0 (en) Non-invasive disease detection and monitoring
GB202215319D0 (en) Non-invasive disease detection and monitoring
EP3991654A4 (en) BIOMEDICAL ELECTRODE, BIOMEDICAL SENSOR AND BIOSIGNAL MEASUREMENT SYSTEM
SG11202110152SA (en) Method and device for a non-invasive determination and/or monitoring of intracranial compliance
WO2009005549A3 (en) Angiogenesis monitoring using in vivo hyperspectral radiometric imaging
EP3946035A4 (en) ELECTRODES FOR DETECTING PHYSIOLOGICAL SIGNALS AND PERFORMANCE MONITOR THEREOF
IL310733A (en) Melanin bias reducing pulse oximeter and accompanied patient monitoring technology
AU2021901783A0 (en) Non-invasive bioanalyte detection and monitoring

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)